Johns Hopkins The Cervical Cancer Research Lab of
Drs. T.-C. Wu & Chien-Fu Hung

MOST RECENT PUBLICATIONS

The following publications (106 of 211 publications) are a compilation of journal and review articles as well as book chapters that highlight advances in our current research and knowledge of vaccines against HPV-associated cervical cancer.

  1. S. Peng, A. Monie, T. H. Kang, C.-F. Hung, R.Roden and T.-C. Wu. (2010) Efficient Delivery of DNA Vaccines using Human Papillomavirus Pseudovirions. Gene Therapy (in press).
  2. Y.-Q. Zhang, YC Tsai, Monie A, CF Hung, and T.-C. Wu. (2010) Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine. Jun 9. [Epub ahead of print]
  3. CM Chuang, A Monie, CF Hung, and T.-C. Wu. (2010) Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci. Apr 28;17:32.
  4. B. Ma, Y. Xu, C.-F. Hung, and T.-C. Wu. (2010) HPV and Therapeutic Vaccines: Where are We in 2010? Current Cancer Therapy Reviews. May; 6(2): 81-103.
  5. Y.-Q. Zhang, Y.-C. Tsai, A. Monie, T.-C. Wu and C.-F. Hung. (2010) Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific Immunotherapy. Mol Ther. 2010 Apr;18(4):692-9. Epub 2010 Jan 19.
  6. J.-H. Su, A. Wu, E. Scotney, B. Ma, A. Monie, C.-F. Hung, and T.-C. Wu. (2010) Immunotherapy for Cervical Cancer: Research Status and Clinical Potential. BioDrugs Apr 1;24(2):109-29.
  7. C.-P. Mao, C.-F. Hung, T. H. Kang, L. He, Y.-C. Tsai, C.-Y. Wu, T.-C. Wu. (2010) Combined Administration with DNA Encoding Vesicular Stomatitis Virus G Protein Enhances DNA Vaccine Potency. J Virol Mar;84(5):2331-9. Epub 2009 Dec 16.
  8. Lin, K. Doolan, C.-F. Hung and T-C Wu. (2010) Perspectives for Preventive and Therapeutic HPV Vaccines. J Formos Med Assoc. Jan;109(1):4-24.
  9. CL Trimble, S Peng, C Thoburn, F Kos, T.-C. Wu. (2010) Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother. 59(5):799-803. Epub 2009 Dec 13.
  10. C.-P. Mao and T.-C. Wu. (2010) Inhibitory RNA Molecules in Immunotherapy for Cancer. RNA Interference: From Biology to Clinical Applications. Methods Mol Biol. 2010;623:325-39.
  11. K. Lin, E. Roosinovich, B. Ma, C.-F. Hung, and T.-C. Wu. (2010) Therapeutic HPV DNA Vaccines. Immunol Res. Jan 12.
  12. CF Hung, A Monie, WH Weng, T.-C. Wu. (2010) DNA vaccines for cervical cancer. Am J Transl Res. Jan 2;2(1):75-87.
  13. T.H. Kang, K.H. Noh, J.H. Kim, H.C. Bae, K.Y. Lin, A. Monie, S.I. Pai, C.F. Hung, T.-C. Wu, and T.-W. Kim. (2010) Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res. 15:70(8):3062-70.
  14. C. L. Trimble, S. Peng, F. Kos, P. Gravitt, R. Viscidi, E. Sugar, D. Pardoll, T.-C. Wu (2009) A phase I trial of a HPV DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clinical Cancer Research 15(1):361-7.
  15. C. W. Tseng, C. L. Trimble, Q. Zeng, A. Monie, R. D. Alvarez, W. K. Huh, T. Hoory, M. C. Wang, C.-F. Hung, T.-C. Wu. (2009) Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother. May;58(5):737-48.
  16. SR Best, S Peng, CM Juang, CF Hung, D Hannaman, JR Saunders, T.-C. Wu, SI Pai. (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 27(40):5450-9.
  17. C.-L. Chang, B. Ma, X.W. Pang, T.-C. Wu and C.-F. Hung. (2009) Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther. 17(8):1365-72.
  18. Kyung Hee Noh, Tae Heung Kang, Jin Hee Kim, Sara I. Pai, Ken Y. Lin, Chien-Fu Hung, T.-C. Wu and Tae Woo Kim. (2009) Activation of Akt as a mechanism for tumor immune evasion. Molecular Therapy 17(3):439-47.
  19. SW Tsen, CY Wu, A Meneshian, SI Pai, CF Hung and T.-C. Wu. (2009) Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J Biomed Sci. 16:36.
  20. J. Rowley, A. Monie, C.F. Hung and T.-C. Wu (2009) Expression of IL-15R? or an IL-15/IL-15R? fusion can promote IL-15 mediated survival and proliferation of CD8+ T cell in cis. European Journal of Immunology 39(2):491-506.
  21. T.H. Kang, J-Y Chung, A Monie, SI Pai, C-F Hung and T.-C. Wu. (2009) Enhancing DNA vaccine potency by co-administration of xenogenic MHC-class-I DNA. Gene Therapy 2010 Apr; 17(4):531-40. [Epub 2010 Nov 26]
  22. A. Monie, S-W D. Tsen, C.-F. Hung and T.-C. Wu. (2009) Therapeutic HPV DNA Vaccines. Expert Review of Vaccines. 8(9):1221-35.
  23. K.T. Tsen, S.W. Tsen, Q. Fu, S.M. Lindsay, K. Kibler, B. Jacobs, T.-C. Wu, B. Karanam, S. Jagu, R.B. Roden, C.-F. Hung, O.F. Sankey, B. Ramakrishna, and J.G. Kiang. (2009) Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt. 14(6):06042.
  24. D. Kim, R. Gambhira, B. Karanam, A. Monie, C.-F. Hung, R. Roden and T.-C. Wu (2008) Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 26: 351-360.
  25. C.-W. Tseng, C.-F. Hung, R. D. Alvarez, C. L. Trimble, W. K. Huh, D. Kim, C.-M. Chuang, C.-T. Lin, Y.-C. Tsai, L. He, A. Monie and T.-C. Wu (2008) Pretreatment with cisplatin enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Clinical Cancer Research 14: 3193-3203.
  26. C.-F. Hung, B. Ma, A. Monie, S.-W. Tsen and T.-C. Wu (2008) Therapeutic HPV vaccines: current clinical trials and future directions Expert Opinion of Biological Therapy 8: 421-439.
  27. D. Kim, T. Hoory, A. Monie, J. P.-Y. Ting, C.-F. Hung and T.-C. Wu (2008) Enhancement of DNA vaccine potency through co-administration of MHC Class II Transactivator (CIITA) DNA with DNA vaccines via gene gun. Journal of Immunology 180: 7019-7027.
  28. T. Hoory, A. Monie, P. Gravitt and T.-C. Wu (2008) Molecular Epidemiology of Human Papillomavirus. Journal of Formosa Medical Association 3: 198-217.
  29. C.W. Tseng, A. Monie, C.Y. Wu, B. Huang, M-C. Wang, C.F. Hung and T.-C. Wu (2008) Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Journal of Molecular Medicine 86(8): 899-908.
  30. D. Kim, A. Monie, L. He, Y.-C. Tsai, C.-F. Hung and T.-C. Wu (2008) Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7 specific CD8+ T cell immune responses. Gene Therapy 15: 677-687.
  31. B. Huang, C.-P. Mao, S. Peng, M.-C. Wang, C.-F. Hung and T.-C. Wu (2008) RNA interference-mediated in vivo silencing of FasL as a strategy for the enhancement of DNA vaccine potency. Human Gene Therapy 19(8): 763-773.
  32. C.W. Tseng, A. Monie, C. Trimble, R. D. Alvarez, W. K. Huh, D. J. Buchsbaum, J. M. Straughn Jr., M-C. Wang, H. Yagita, C.-F. Hung and T.-C. Wu (2008) Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. Vaccine 26(34): 4314-4319.
  33. S. Peng, C. L. Trimble, R. D. Alvarez, W. K. Huh, Z. Lin, A. Monie, C.-F. Hung and T.-C. Wu (2008) Cluster Intradermal DNA Vaccination Rapidly Induces E7-specific CD8+ T Cell Immune Responses Leading to Therapeutic Antitumor Effects. Gene Therapy 15: 677-687.
  34. C.-F. Hung, T.-C.Wu, A. Monie and R. Roden (2008) Antigen-specific immunotherapy of cervical and ovarian cancer. Immunological Reviews 222: 43-69.
  35. J. Rowley, A. Monie, C.F. Hung and T.-C. Wu (2008) Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans. Journal of Immunology 181(12):8237-47.
  36. D. Kim, A. Monie, Y.-C. Tsai, L. He, M.-C. Wang, C.-F. Hung and T.-C. Wu (2008) Enhancement of CD4+ T cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Therapy 15(16): 1176-1183.
  37. D. Kim, T. Hoory, T.-C. Wu and C.-F. Hung (2007) Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cells. Gene Therapy. 18: 1129-1139.
  38. C.-F. Hung, R. Calizo, Y.-C. Tsai, L. He, and T.-C. Wu (2007) A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 25: 127-135.
  39. C.-F. Hung, Y.-C. Tsai, L. He, and T.-C. Wu (2007) DNA Vaccines Encoding Ii-PADRE generates potent PADRE-specific CD4+ T cell immune responses and enhances vaccine potency. Molecular Therapy 15: 1211-1219.
  40. T. H. Kang, J. H. Lee, C. K. Song, H. D. Han, B. C. Shin, S. I. Pai, C.-F. Hung, C. Trimble, J.-S. Lim, T. W. Kim and T.-C. Wu (2007) Epigallocatechin-3-Gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Research 67: 802-811.
  41. S.-W. D. Tsen, A. Paik, C.-F. Hung and T-C Wu (2007) Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Review of Vaccines 6: 227-239.
  42. T.-C. Wu (2007) The role of VCAM-1 in tumor Immune evasion. Cancer Research 67: 6003-6007.
  43. C.-F. Hung, A. Monie, R. D. Alvarez and T.-C. Wu (2007) DNA vaccines for cervical cancer: from bench to bed side. Experimental and Molecular Medicine 39: 679-689.
  44. C.-F. Hung, Y.-C. Tsai, L. He, G. Coukos, I. Fodor, L. Qin, H. Levitsky and T.-C. Wu (2007) Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Therapy 14: 20-29.
  45. K.-Y. Lin, D. Lu, C.-F. Hung, S. Peng, L Huang, C. Jie, F. Murillo, J. Rowley, Y.-C. Tsai, L. He, E. Jaffee, D. M. Pardoll and T.-C. Wu (2007) Ectopic expression of vascular cell adhesion molecule-1 (VCAM-1) as a new mechanism for tumor immune evasion. Cancer Research 67: 1832-1841.
  46. C.-F. Hung, Y.-C. Tsai, L. He, and T.-C. Wu (2007) Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Therapy 14: 921-929.
  47. C.-P. Mao, C.-F. Hung and T.-C. Wu (2007) Immunotherapeutic Strategies Employing RNA Interference Technology for the Control of Cancers, J. Biomed. Sci 14: 15-29.
  48. C.-P. Mao, Y.-Y. Lin, C.-F. Hung and T.-C. Wu (2007) Immunological research using RNA interference technology. Immunology. 121: 295-307.
  49. B. Huang, C.P. Mao, S.W. Peng, L.M. He, C.F. Hung, and T.-C. Wu. (2007) Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell surival enhances DNA vaccine potency. Vaccine 25: 7824-7831.
  50. Chang, C.L., T.C. Wu, and C.F. Hung, (2007) Control of human mesothelin-expressing tumors by DNA vaccines. Gene Therapy 14: 1189-1198.
  51. S. Peng, C. Trimble, L. Wu, D. Pardoll, C.-F. Hung, and T.-C. Wu (2007) HLA-DQB1*02-Restricted HPV-16 E7 Peptide-specific CD4+ T Cell Immune Responses Correlate with Regression of HPV-16-Associated High Grade Squamous Intraepithelial Lesions Clinical Cancer Research 13: 2479-2487.
  52. R. Roden, A. Monie and T.-C. Wu (2007) Opportunities to improve the prevention and treatment of cervical cancer. Current Molecular Medicine. 7: 490-503.
  53. T.-C. Wu (2007) Therapeutic HPV DNA vaccination strategies to control cervical cancer. (commentary) European Journal of Immunology 37: 310-314.
  54. Kang, T. H., J. H. Lee, K. H. Noh, H. D. Han, B. C. Shin, E. Y. Choi, S. Peng, C. F. Hung, T.-C. Wu, and T. W. Kim. (2007). Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 120:1696-1703.
  55. D. Kim, C.-F. Hung and T.-C. Wu (2007) Monitoring the trafficking of adoptively transferred antigen-specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther 18: 575-588.
  56. K.T. Tsen, S.-W. D. Tsen, C.-L. Chang, C.-F. Hung, T.-C. Wu and Juliann G. Kiang (2007) Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virology J. 4: 50-55.
  57. C.-L. Chang, Y.-C. Tsai, L. He, T.-C. Wu, and C.-F. Hung (2007) Cancer immunotherapy using irradiated tumor cells secreting Hsp70. Cancer Research 67: 10047-10057.
  58. C. M. Juang, C. F. Hung, J. Y. Yeh, H. C. Horng, N. F. Twu, M. H. Cheng, K. C. Wen, C. C. Yuan, K. C. Chao, T. C. Wu, and M. S. Yen. (2007). Regulatory T cells: potential target in anticancer immunotherapy. Taiwan J Obstet Gynecol 46:215-221.
  59. Y.-Y. Lin, H. Alphs, C.-F. Hung, R.B.S. Roden and T.-C. Wu (2007) Vaccines against human papillomavirus. Frontiers in Bioscience 12: 246-264.
  60. K.T. Tsen, S.-W. D. Tsen, C.-L. Chang, C.-F. Hung, T.-C. Wu and Juliann G. Kiang (2007) Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process. Journal of Biomedical Optics 12: 064030.
  61. W.-F. Cheng, C.-F. Hung, C.-Y. Chai, C.-A. Chen, C.-N. Lee, Y.-N. Su, W.-Y. I. Tseng, C.-Y. Hsieh, I.-M. Shih, T.-L. Wang and T.-C. Wu (2007) Generation and characterization of an ascitogenic Mesothelin-Expressing Tumor Model. Cancer 110: 420-431.
  62. A. Monie, Chien-Fu Hung and T.-C. Wu (2007) Preventive and Therapeutic HPV Vaccines. Current Opinion in Investigational Drugs 8:1038-50.
  63. A. Monie, C.-F. Hung, R. Roden and T.-C. Wu (2007) Cervarix: A vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics: Targets & Therapy 2.
  64. C.-P. Mao, C.-F. Hung and T-C Wu (2007) Cancer Immunotherapy Using RNAi. European Pharmaceutical Review 12: 13-19.
  65. H. H. Alphs, T.-C. Wu, R. B.S. Roden (2007) Prevention and treatment of cervical cancer by vaccination. Book Chapter of Molecular Pathology of Gynecologic Cancer, Editors A. Giordano, A. Bovicelli and R.J. Kurman Chapter 9: 125-153.
  66. S. W.D. Tsen, C.-F. Hung, and T.-C. Wu (2007) Antigen-specific cancer immunotherapy: HPV-associated cervical cancer as a model system. Book Chapter of Cancer Vaccines and Tumor Immunology, Editors B. Johnson, R. Orentas and J. Hodge Chapter 6.
  67. R. Roden, A. Monie and T.-C. Wu (2007) Human papillomavirus vaccine for cervical cancer prevention. Management of Cervical Cancer. Editor: Dan Longo in Hot Topics in Oncology.
  68. C.-F. Hung, A. Monie and T.-C. Wu (2007) Immunotherapy of Angiogenesis with DNA Vaccines. Book Chapter of Angiogenesis: An integrative approach from science to medicine. Editors: Drs. William D. Figg and Judah Folkman. Springer US. Chapter 39: pp 451-460.
  69. S.-W. D. Tsen, C.-F. Hung and T.-C. Wu (2007) Antigen-specific cancer immunotherapy: HPV-associated cervical cancer as a model system. Book Chapter of Cancer Vaccines and Tumor Immunity, Edited by Rimas Orentas, James W. Hodge and Bryon D. Johnson. John Wiley& Son, Inc. Chapter 6: pp 79-94.
  70. C.-P. Mao and T.-C. Wu (2007) Molecular pathogenesis of the human papillomavirus. Translational Research in Biomedicine Vol. 1: Human Cancer Viruses Edited by, John Nicholas, Kuan-Teh Jeang and T.-C. Wu., S. Karger AG. 20-36.
  71. R. Roden and T.-C. Wu (2006) How will HPV vaccines affect cervical cancer? Nature Reviews Cancer 6: 753-763.
  72. S. I. Pai, Y.-Y. Lin, B. Macaes, A. Meneshian, C.-F. Hung and T.-C. Wu (2006) Prospects of RNA Interference Therapy for Cancer. Gene Therapy 13: 464-477.
  73. T. W. Kim, C.-F. Hung, J.-H. Lee, L. He, D. A. K. Boyd, J. M. Hardwick and T.-C. Wu (2005) Modification of Professional Antigen-Presenting Cells with Small Interfering RNA In Vivo to Enhance Cancer Vaccine Potency. Cancer Research 65: 309-316.
  74. C.-H. Huang, S. Peng, L. He, Y.-C. Tsai, D. A. K. Boyd, T. H. Hansen, T.-C. Wu and C.-F. Hung (2005) Cancer Immunotherapy Using a DNA Vaccine Encoding a Single-Chain Trimer of MHC class I Linked to an HPV-16 E6 Immunodominant CTL Epitope. Gene Therapy 12: 1180-1186.
  75. A. D. Bins, A. Jorritsma, M. C. Wolkers, C.-F. Hung, T. -C. Wu, T. N.M. Schumacher and J. B.A.G.Haanen (2005) A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nature Medicine 11: 899-904.
  76. S. Peng, H. Ji, C. Trimble, L. He, Y.-C. Tsai, J. Yeatermeyer, D. A. K. Boyd, C.-F. Hung, and T.-C. Wu (2004) Development of a DNA Vaccine Targeting HPV-16 Oncoprotein E6. J. Virol 78: 8468-8476.
  77. J. W. Kim, C.-F. Hung, J. Juang, L. He, T. W. Kim, D. K. Armstrong, S. I. Pai, C.-T. Lin, and T. -C. Wu (2004) Comparison of HPV DNA Vaccines Employing Intracellular Targeting Strategies. Gene Therapy. Feb: 1-8.
  78. T. W. Kim, J. H. Lee, C.-F. Hung, S. Peng, R. Roden, M.-C. Wang, R. Viscidi, Y.-C. Tsai, L. He, P.-J. Chen, D. Boyd and T. -C. Wu (2004) Generation and characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus. J. Virol. 78: 4638-4645.
  79. T. W. Kim, C.-F. Hung, M. Ling, J. Juang, L. He, J. M. Hardwick, S. Kumar, and T.-C. Wu (2003) Enhancing DNA vaccine potency by co-administration of DNA encoding anti-apoptotic proteins. J. Clin. Invest. 112: 109-117.
  80. C. Trimble, C.-T. Lin , C.-F. Hung, S. Pi, J. Juang, L. He, M. Gillison, D. Pardoll, Lee Wu, and T. -C. Wu (2003) Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 21: 4036-4042.
  81. T.W. Kim, C.-F. Hung, D. Boyd, J. Juang, L. He, J. W. Kim, J. M. Hardwick, and T.-C. Wu (2003) Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life with Intracellular Targeting Strategies. J. Immunol. 171: 2970-2976.
  82. C.-F Hung, W.-F. Cheng, L. He, M. Ling, J. Juang, and T.-C. Wu (2003) Enhancing MHC class I antigen presentation by targeting antigen to centrosomes. Cancer Research. 63: 2393-2398.
  83. C.-F. Hung and T.-C. Wu (2003) Improving DNA vaccine potency via modification of professional antigen presenting cells. Current Opinion in Molecular Therapeutics 5: 20-24.
  84. W.-F. Cheng, C.-F. Hung, K.-F. Hsu, C.-Y. Chai, L. He, J. M. Polo, L. A. Slater, M. Ling, and T.-C. Wu (2002) Cancer immunotherapy using sindbis virus replicon particles encoding a VP22-antigen fusion. Human Gene Therapy 13: 553-568.
  85. C.-F. Hung, L. He, J. Juang, T.-J. Lin, M. Ling, and T.-C. Wu (2002) Improving DNA vaccine potency by linking Marek�s disease virus type 1 VP22 to an antigen. J. Virol. 76: 2676-2682.
  86. C.-F. Hung, W.-F. Cheng, K.-F. Hsu, C.-Y. Chai, L. He, M. Ling and T.-C. Wu (2001) Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Research. 61: 3698-3703.
  87. W.-F. Cheng, C.-F. Hung, C.-Y. Chai, K.-F. Hsu, L. He, M. Ling and T.-C. Wu (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108: 669-78.
  88. W.-F. Cheng, C.-F. Hung, C.-Y. Chai, K.F. Hsu, L. He, M. Ling, and T.-C. Wu (2001) Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 75(5):2368-76.
  89. W.-F. Cheng, C.-F. Hung, C.-Y. Chai, K.-F. Hsu, L. He, M. Ling and T.-C. Wu (2001) Enhancing sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1(HSV-1) VP22 protein to antigen. J Virology 75:2368-2376.
  90. C.-F. Hung, W.-F. Cheng, Chai, C.-Y., K.-F. Hsu, L.He, M. Ling and T.-C. Wu (2001) Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J. Immunol. 166: 5733-5740.
  91. K.-F. Hsu, C.-F. Hung, W.-F. Cheng, L. He, M. Ling and T.-C. Wu (2001) Enhancement of suicidal DNA vaccine potency by linking Mycobacterium Tuberculosis heat shock protein 70 to an antigen. Gene Therapy 8: 376-383.
  92. C.-F. Hung, K.-F. Hsu, W.-F. Cheng, C.-Y. Chai, L. He, M. Ling and T.-C. Wu (2001) Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Research. 61: 1080-1088.
  93. W.-F. Cheng, C.-F. Hung, C.-Y. Chai, K.-F. Hsu, L. He, C. M. Rice, M. Ling, and T.-C. Wu (2001) Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium Tuberculosis heat shock protein 70 gene to an antigen gene. J. Immunol. 166: 6218-6226.
  94. T.-L. Wang, M. Ling, I.-M. Shih, T.Pham, S.I. Pai, Z. Lu, R.J. Kurman, D.M. Pardoll, and T.-C. Wu (2000) Intramuscular administration of E7-transduced dendritic cells generates the most potent E7-specific antitumor immunity. Gene Therapy, 7: 726-733.
  95. C.-H. Chen, T.-L. Wang, C.-F. Hung, Y. Yang, H. Chen, R. A. Young, D. M. Pardoll and T.-C. Wu (2000) Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Research, 60:1035-1042.
  96. C.-H. Chen, T.-L. Wang, C.-F. Hung, D. M. Pardoll and T.-C. Wu (2000) Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine, 18: 2015-2022.
  97. E.Y. Chang, C.H. Chen, H. Ji, T.-L. Wang, K. Hung, B.L. Lee, A.Y.C. Huang, R.J. Kurman, D.M. Pardoll, T.-C. Wu (2000) Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int. J. Cancer, 86: 725-730.
  98. H. Ji, T.-L.Wang, C.-H. Chen,S. I. Pai, C.-F. Hung, K.-Y. Lin, R. J. Kurman, D. M. Pardoll and T.-C. Wu (1999) Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Human Gene Therapy, 10: 2727-2740.
  99. C.-H. Chen, H. Ji, K. W. Suh, M. A. Choti, D. M. Pardoll and T.-C. Wu (1999) Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Therapy, 6: 1972-1981.
  100. H. Ji, E.Y. Chang, K.-Y. Lin, R.J. Kurman, D.M. Pardoll, and T.-C. Wu (1998) Antigen-specific immunotherapy for murine lung metastatic tumors expressing HPV-16 E7 oncoprotein Int. J. Cancer 78:41-45.
  101. K.-Y. Lin, F. G. Guarnieri, K. F. Staveley-O'Carroll, H. I. Levitsky, J. T. August, D. M. Pardoll and T.-C. Wu (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Research 56:21-26.
  102. T.-C. Wu, F.G. Guarnieri, K.F. Staveley-O'Carroll, R.P. Viscidi, H.I. Levitsky, L. Hedrick, K.R. Cho, J.T. August, and D.M. Pardoll (1995) Engineering an intracellular pathway for MHC Class II Presentation of Antigens. Proc. Natl. Acad. Sci. 92: 11671-11675.
  103. T.-C. Wu, A. Y.C. Huang, E. M. Jaffee, and D. M. Pardoll (1995) A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182: 1415-1421.
  104. T.-C. Wu, R.H. Hruban, R.F. Ambinder, M.Pizzorno, D.E. Cameron, W.A. Baumgartner, B.A. Reitz, G.S. Hayward, and G.M. Hutchins (1992). Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. American J. Pathology 140: 739-747.
  105. T.-C. Wu, R.B. Mann, J. Epstein, E. MacMahon, W.A. Lee, P. Charache, S.D. Hayward, R.J. Kurman, G.S. Hayward, and R.F. Ambinder (1991). Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma: A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens: American J. Pathology 138:1461-1469.
  106. T.-C. Wu, R.B. Mann, P. Charache, S.D. Hayward, S.Staal, B.C. Lambe and R.F. Ambinder. (1990) Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int. J. Cancer Vol. 46, pp 801-804.